depymed_logo.png
DepYmed and Monash Biomedicine Discovery Institute to Study the Role of a New Generation of PTP1B Inhibitors against a Novel Intracellular Checkpoint in Cancer
10 mars 2022 09h45 HE | DepYmed, Inc.
Research Agreement Capitalizes on Newly Published Monash Findings in Peer Reviewed Journal Cancer Discovery1 that PTP1B acts as an Intracellular Checkpoint and PTP1B Inhibition Represses Tumor Growth ...